Bonraybio Co., Ltd. (6955.TWO)

Bonraybio Co., Ltd. (6955.TWO) — VMCI valuation read

The headline on Bonraybio Co., Ltd. (6955.TWO) is a 57/100 VMCI score, set against a broad-market sample median of 50. That 7-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

6955.TWO insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** 6955.TWO trades at 23.0x earnings, 28% above the sector median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the sector median (10.0%) sets the quality side. Net debt to EBITDA of 2.5x is the rate-sensitivity line to watch sets the risk side, the three lines a value buyer reads first on 6955.TWO.

6955.TWO fell 0.3% over the trailing 7 days, with a -18.6% read on a 30-day basis.